WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

19 September 2017

TiGenix Business and Financial Update for the First Half 2017 (EN – NL – FR – ES)

Webcast Replay (EN) – Webcast Presentation (EN)

Financial statements (ENNL)

12 September 2017

TiGenix strengthens US operations with senior appointments (ENNLFRES)

UPCOMING EVENTS

  • INVESTORS AND PARTNERING
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
24.00 USD
Change (%):
0.02 (0.08%)
BRU
1.01 EUR
Change (%):
-0.00 (-0.30%)